ZA200905467B - Method for activation of helper T cell and composition for use in the method - Google Patents
Method for activation of helper T cell and composition for use in the methodInfo
- Publication number
- ZA200905467B ZA200905467B ZA200905467A ZA200905467A ZA200905467B ZA 200905467 B ZA200905467 B ZA 200905467B ZA 200905467 A ZA200905467 A ZA 200905467A ZA 200905467 A ZA200905467 A ZA 200905467A ZA 200905467 B ZA200905467 B ZA 200905467B
- Authority
- ZA
- South Africa
- Prior art keywords
- helper
- activation
- cell
- composition
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 210000002443 helper t lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007047317 | 2007-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200905467B true ZA200905467B (en) | 2010-05-26 |
Family
ID=39721287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200905467A ZA200905467B (en) | 2007-02-27 | 2009-08-05 | Method for activation of helper T cell and composition for use in the method |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10139395B2 (zh) |
| EP (1) | EP2119778B1 (zh) |
| JP (2) | JP5225262B2 (zh) |
| KR (1) | KR101598228B1 (zh) |
| CN (6) | CN103149366B (zh) |
| AU (1) | AU2008220031B2 (zh) |
| BR (1) | BRPI0808084A2 (zh) |
| CA (1) | CA2677075C (zh) |
| CY (1) | CY1117150T1 (zh) |
| DK (1) | DK2119778T3 (zh) |
| ES (1) | ES2559062T3 (zh) |
| HK (1) | HK1138321A1 (zh) |
| HR (1) | HRP20160020T1 (zh) |
| HU (1) | HUE027472T2 (zh) |
| IL (1) | IL200161A (zh) |
| MX (2) | MX2009009168A (zh) |
| MY (2) | MY164867A (zh) |
| NZ (3) | NZ599161A (zh) |
| PL (1) | PL2119778T3 (zh) |
| PT (1) | PT2119778E (zh) |
| RU (2) | RU2009135802A (zh) |
| SG (1) | SG177998A1 (zh) |
| SI (1) | SI2119778T1 (zh) |
| UA (1) | UA101608C2 (zh) |
| WO (1) | WO2008105462A1 (zh) |
| ZA (1) | ZA200905467B (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| AU2008220031B2 (en) | 2007-02-27 | 2013-06-13 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
| AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| CN102762719A (zh) | 2009-12-08 | 2012-10-31 | 威尔森沃尔夫制造公司 | 用于过继细胞疗法的细胞培养的改进方法 |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| AU2011313327B2 (en) * | 2010-10-05 | 2015-10-22 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| BR112014002747A2 (pt) | 2011-09-14 | 2020-10-27 | International Institute Of Cancer Immunology, Inc | método para medir um anticorpo anti-wt1 |
| JP6218175B2 (ja) * | 2011-12-14 | 2017-10-25 | 国立大学法人高知大学 | ヘルパーｔ細胞誘導性ポリペプチドの改変 |
| US20150104413A1 (en) | 2012-01-13 | 2015-04-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| CN104797711B (zh) * | 2012-09-12 | 2018-09-21 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
| SG10201705028WA (en) | 2012-12-17 | 2017-07-28 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
| EP3769782A1 (en) | 2013-01-15 | 2021-01-27 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| EP3112378B1 (en) * | 2014-02-26 | 2020-06-24 | Tella, Inc. | Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide |
| JP6770269B2 (ja) | 2015-06-25 | 2020-10-14 | 国立大学法人神戸大学 | 経口腫瘍ワクチン |
| EP3560513A4 (en) | 2016-12-26 | 2020-10-14 | National University Corporation Kobe University | ANTICANCER THERAPY USING A COMBINATION OF AN ORAL TUMOR VACCINE AND AN IMMUNOSUPPRESSION INHIBITOR |
| CN116134131A (zh) | 2019-12-31 | 2023-05-16 | 伊利克斯根治疗公司 | 核酸和蛋白质向细胞和组织的基于温度的瞬时递送 |
| KR102647825B1 (ko) * | 2021-07-22 | 2024-03-14 | 서울대학교산학협력단 | 항-hla-dp 단클론 항체 및 이의 용도 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| WO2000006602A1 (fr) | 1998-07-31 | 2000-02-10 | Haruo Sugiyama | Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1 |
| IL142216A0 (en) | 1998-09-30 | 2002-03-10 | Corixa Corp | A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| CA2401070A1 (en) | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| BRPI0208183B8 (pt) * | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| EP2014300B1 (en) | 2001-06-29 | 2011-01-12 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome |
| US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| US20050002951A1 (en) | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
| AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
| EP1550453B1 (en) | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptide preparation |
| WO2004026897A1 (ja) | 2002-09-20 | 2004-04-01 | Chugai Seiyaku Kabushiki Kaisha | Ｗｔ１置換型ペプチド |
| AU2004204031B2 (en) | 2003-01-15 | 2010-03-04 | International Institute Of Cancer Immunology, Inc. | Dimerized peptide |
| KR101292971B1 (ko) | 2003-06-27 | 2013-08-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ1 백신 적응 환자의 선택 방법 |
| CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| AU2004294345B2 (en) * | 2003-12-01 | 2012-02-23 | Sloan-Kettering Institute For Cancer Research | Synthetic HLA binding peptide analogues and uses thereof |
| WO2005095598A1 (ja) | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Ｗｔ１由来の癌抗原ペプチド |
| JP4719876B2 (ja) * | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| AU2006319892B2 (en) | 2005-11-30 | 2012-05-10 | International Institute Of Cancer Immunology, Inc. | Novel peptide compound |
| DK1988163T3 (da) | 2006-02-22 | 2012-08-20 | Int Inst Cancer Immunology Inc | Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme |
| US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| ES2629578T3 (es) | 2006-12-28 | 2017-08-11 | International Institute Of Cancer Immunology, Inc. | Péptido WT1 restringido a HLA-A*1101 y una composición farmacéutica que comprenden el mismo |
| AU2008220031B2 (en) | 2007-02-27 | 2013-06-13 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
| MX343633B (es) | 2007-03-05 | 2016-11-11 | Int Inst Cancer Immunology Inc | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| AU2011313327B2 (en) | 2010-10-05 | 2015-10-22 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| SG10201705028WA (en) | 2012-12-17 | 2017-07-28 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
-
2008
- 2008-02-27 AU AU2008220031A patent/AU2008220031B2/en active Active
- 2008-02-27 MX MX2009009168A patent/MX2009009168A/es active IP Right Grant
- 2008-02-27 CN CN201310058504.4A patent/CN103149366B/zh active Active
- 2008-02-27 CN CN200880006096A patent/CN101622344A/zh active Pending
- 2008-02-27 CA CA2677075A patent/CA2677075C/en active Active
- 2008-02-27 SI SI200831564T patent/SI2119778T1/sl unknown
- 2008-02-27 CN CN201310009095.9A patent/CN103103246B/zh active Active
- 2008-02-27 EP EP08712039.0A patent/EP2119778B1/en active Active
- 2008-02-27 CN CN201510102294.3A patent/CN104774910B/zh active Active
- 2008-02-27 SG SG2012004180A patent/SG177998A1/en unknown
- 2008-02-27 KR KR1020097017594A patent/KR101598228B1/ko active IP Right Grant
- 2008-02-27 MX MX2014002596A patent/MX352947B/es unknown
- 2008-02-27 PL PL08712039T patent/PL2119778T3/pl unknown
- 2008-02-27 JP JP2009501276A patent/JP5225262B2/ja active Active
- 2008-02-27 UA UAA200909812A patent/UA101608C2/uk unknown
- 2008-02-27 HU HUE08712039A patent/HUE027472T2/en unknown
- 2008-02-27 MY MYPI2013001057A patent/MY164867A/en unknown
- 2008-02-27 RU RU2009135802/10A patent/RU2009135802A/ru unknown
- 2008-02-27 BR BRPI0808084-4A patent/BRPI0808084A2/pt not_active Application Discontinuation
- 2008-02-27 NZ NZ599161A patent/NZ599161A/xx unknown
- 2008-02-27 MY MYPI20093253A patent/MY158219A/en unknown
- 2008-02-27 WO PCT/JP2008/053417 patent/WO2008105462A1/ja active Application Filing
- 2008-02-27 CN CN201410573477.9A patent/CN104312974B/zh active Active
- 2008-02-27 PT PT87120390T patent/PT2119778E/pt unknown
- 2008-02-27 US US12/449,765 patent/US10139395B2/en active Active
- 2008-02-27 NZ NZ599160A patent/NZ599160A/en unknown
- 2008-02-27 RU RU2014104572A patent/RU2680539C2/ru active
- 2008-02-27 ES ES08712039.0T patent/ES2559062T3/es active Active
- 2008-02-27 NZ NZ578721A patent/NZ578721A/en unknown
- 2008-02-27 CN CN201310009518.7A patent/CN103088103B/zh active Active
- 2008-02-27 DK DK08712039.0T patent/DK2119778T3/en active
-
2009
- 2009-07-30 IL IL200161A patent/IL200161A/en active IP Right Grant
- 2009-08-05 ZA ZA200905467A patent/ZA200905467B/xx unknown
-
2010
- 2010-05-04 HK HK10104389.9A patent/HK1138321A1/zh unknown
-
2013
- 2013-01-31 JP JP2013017370A patent/JP5714619B2/ja active Active
-
2016
- 2016-01-11 HR HRP20160020TT patent/HRP20160020T1/hr unknown
- 2016-01-20 CY CY20161100054T patent/CY1117150T1/el unknown
-
2018
- 2018-10-18 US US16/163,682 patent/US11555814B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL200161A0 (en) | Method for activation of helper t cell and composition for use in the method | |
| IL267138A (en) | Improved composition of cells and methods for its preparation | |
| GB2443823B (en) | Devices and methods for use in construction | |
| SG10201605686XA (en) | Polishing Composition And Polishing Method Using The Same | |
| IL202329A0 (en) | Methods and compositions for stimulating cells | |
| EP2180933A4 (en) | POROUS BODIES AND METHODS | |
| ZA200905886B (en) | Methods and kits for administering probiotics | |
| EP2189519A4 (en) | CELL CULTURE INSTRUMENT AND CELL CUKLTURE PROCESS WITH THIS | |
| HK1147254A1 (en) | 5-anilinoimidazopyridines and methods of use 5- | |
| EP2129429A4 (en) | ANCHORING APPARATUS AND METHODS OF USE | |
| EP2308884A4 (en) | PROCESS FOR THE PREPARATION OF HETEROSUBSTITUTED ALKYLHALOHYDROSILANE AND ITS USE | |
| EP2324956A4 (en) | POLISHING COMPOSITION AND THIS USE POLISHING METHOD | |
| GB0605702D0 (en) | Materials and methods for immune cell stimulation | |
| GB0709781D0 (en) | Composition and method | |
| GB0724967D0 (en) | Composition and method | |
| GB0905971D0 (en) | Antitussive composition and method for making the same | |
| GB0620930D0 (en) | Composition and method for use thereof | |
| ZA201004894B (en) | Nuctraceutical composition and methods of use | |
| EP2115127A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING CELL HEALTH IN CULTURES | |
| ZA201004893B (en) | Nuctraceutical composition and methods of use | |
| ZA201008261B (en) | Non-hydrating plaster composition and method | |
| MY152929A (en) | Polishing composition and polishing method | |
| EP2348865A4 (en) | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE | |
| EP2185685A4 (en) | NEW PROCESSES AND NEW CELL LINES | |
| TWI365216B (en) | Polishing composition for polishing lithium aluminate and method of using the same |